Pelthos Therapeutics Reports Material Agreements & Equity Sales

Ticker: PTHS · Form: 8-K · Filed: 2025-07-02T00:00:00.000Z

Sentiment: neutral

Topics: acquisition, debt, equity-sale, corporate-action

TL;DR

Pelthos Therapeutics filed an 8-K detailing acquisitions, new debt, equity sales, and control changes. Big moves happening.

AI Summary

Pelthos Therapeutics Inc. filed an 8-K on July 2, 2025, reporting several material events. These include entering into a definitive agreement, the completion of an acquisition, and the creation of financial obligations. The company also disclosed unregistered sales of equity securities and material modifications to security holder rights. Additionally, there were changes in the company's control and updates regarding executive officers and directors.

Why It Matters

This 8-K filing indicates significant corporate actions by Pelthos Therapeutics, including potential acquisitions and financial restructuring, which could impact its future operations and shareholder value.

Risk Assessment

Risk Level: medium — The filing details multiple significant events including acquisitions, financial obligations, and equity sales, which inherently carry business and financial risks.

Key Players & Entities

FAQ

What was the nature of the material definitive agreement entered into by Pelthos Therapeutics?

The filing indicates Pelthos Therapeutics entered into a Material Definitive Agreement, but the specific details of this agreement are not provided in the provided text.

What was acquired or disposed of in the completion of an acquisition or disposition of assets?

The filing confirms the completion of an acquisition or disposition of assets, but the specific assets or entities involved are not detailed in the provided text.

What are the details of the financial obligations created by Pelthos Therapeutics?

The filing states the creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement, but the specific terms and amounts are not disclosed in the provided text.

What was the purpose and amount of the unregistered sales of equity securities?

The filing reports unregistered sales of equity securities, but the specific details regarding the number of shares, price, and recipients are not included in the provided text.

What specific changes occurred regarding the control of Pelthos Therapeutics?

The filing indicates a change in control of the registrant, but the exact nature of this change, such as a new controlling shareholder or merger, is not specified in the provided text.

From the Filing

0001753926-25-001055.txt : 20250702 0001753926-25-001055.hdr.sgml : 20250702 20250702172226 ACCESSION NUMBER: 0001753926-25-001055 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 63 CONFORMED PERIOD OF REPORT: 20250701 ITEM INFORMATION: Entry into a Material Definitive Agreement ITEM INFORMATION: Completion of Acquisition or Disposition of Assets ITEM INFORMATION: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant ITEM INFORMATION: Unregistered Sales of Equity Securities ITEM INFORMATION: Material Modifications to Rights of Security Holders ITEM INFORMATION: Changes in Control of Registrant ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20250702 DATE AS OF CHANGE: 20250702 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Pelthos Therapeutics Inc. CENTRAL INDEX KEY: 0001919246 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences EIN: 863335449 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-41964 FILM NUMBER: 251102609 BUSINESS ADDRESS: STREET 1: 685 US HIGHWAY ONE CITY: NORTH BRUNSWICK STATE: NJ ZIP: 08902 BUSINESS PHONE: 9176446313 MAIL ADDRESS: STREET 1: 685 US HIGHWAY ONE CITY: NORTH BRUNSWICK STATE: NJ ZIP: 08902 FORMER COMPANY: FORMER CONFORMED NAME: Channel Therapeutics Corp DATE OF NAME CHANGE: 20241118 FORMER COMPANY: FORMER CONFORMED NAME: Chromocell Therapeutics Corp DATE OF NAME CHANGE: 20220323 8-K 1 g084856_8k.htm 8-K false --12-31 0001919246 0001919246 2025-07-01 2025-07-01 0001919246 dei:FormerAddressMember 2025-07-01 2025-07-01 iso4217:USD xbrli:shares iso4217:USD xbrli:shares   UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   FORM 8-K   CURRENT REPORT   Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934   Date of Report (Date of earliest event reported): July 1, 2025   Pelthos Therapeutics Inc. (Exact name of registrant as specified in its charter)   Nevada   001-41964   86-3335449 (State or other jurisdiction of incorporation)   (Commission File Number)   (IRS Employer Identification No.)   4020 Stirrup Creek Drive , Suite 110 Durham , NC   27703 (Address of registrant’s principal executive office)   (Zip code)   Registrant’s telephone number, including area code: (877) 265-8266   Channel Therapeutics Corporation 4400 Route 9 South , Suite 1000 Freehold , NJ 07728   (Former name or former address, if changed since last report.)   Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):   ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)   ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)   ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))   ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))   Securities registered pursuant to Section 12(b) of the Act:   Title of each class   Trading Symbol(s)   Name of each exchange on which registered Common Stock, par value $0.0001 per share   PTHS   The NYSE American LLC   Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.40

View on Read The Filing